Assessment of Herb-drug Interactions Based on the Pharmacokinetic Changes of Probe Drug, Midazolam [0.03%]
基于探针药物咪达唑仑的药动学变化评估中草药与药物间的相互作用
Sarvesh Sabarathinam,Thangavel M Vijayakumar
Sarvesh Sabarathinam
Background: In healthy volunteers, the probe drug method is widely practised to assess the pharmacokinetic mediated herb-drug interactions (HDI). We analyzed the clinical evidence of CYP3 A4 probe drug, Midazolam. ...
Pharmacokinetics of Darolutamide, its Diastereomers and Active Metabolite in the Mouse: Response to Saini NK et al. (2020) [0.03%]
达鲁塔莫的药代动力学及其非对映异构体和活性代谢产物在小鼠中的研究——对Saini NK等人（2020）的研究回复
Pirjo Nykänen,Timo Korjamo,Hille Gieschen et al.
Pirjo Nykänen et al.
Background: Saini et al. recently investigated the pharmacokinetics of darolutamide and its diastereomers in vitro and in vivo in Balb/c mice, reporting higher levels of (S,S)-darolutamide than (S,R)-darolutamide followin...
Hemodynamic Assessment and In vivo Catabolism of Adenosine 5'-triphosphate in Doxorubicin or Isoproterenol-induced Cardiovascular Toxicity [0.03%]
多柔比星或异丙肾上腺素引起的心血管毒性中的血流动力学评估及体内三磷酸腺苷的代谢研究
Pollen K Yeung,Sheyda Mohammadizadeh,Fatemeh Akhoundi et al.
Pollen K Yeung et al.
Objective: Previous studies have shown that catabolism of adenosine 5'-triphosphate (ATP) in systemic blood is a potential surrogate biomarker for cardiovascular toxicity. We compared the acute toxicity of high doses of d...
Amorphous Solid Dispersion Based Oral Disintegrating Film of Ezetimibe: Development and Evaluation [0.03%]
依泽替米贝无定形固体分散体基口服崩解膜的开发与评估
Preethi Sudheer,Sangam Shrestha,Kavitha A Narayana
Preethi Sudheer
Background: Ezetimibe is a cholesterol-lowering agent with an oral bioavailability of 50% by virtue of its poor solubility and extensive hepatic and intestinal metabolism. ...
A Short Exploration of Selected Sensitive CYP3A4 Substrates (Probe Drug) [0.03%]
CYP3A4底物药物探针的敏感性研究简述
Sarvesh Sabarathinam,Thangavel M Vijayakumar
Sarvesh Sabarathinam
Background: CYP450 enzymes in the liver have a significant role in the metabolism of xenobiotics. Probe drug strategy is broadly used to evaluate the pharmacodynamic and pharmacokinetic drug/ herb-drug interactions/ food-...
Ahmad A Almeman
Ahmad A Almeman
Background: Cytochrome P450 (CYP) contributes to a huge collection of medicinal products' Phase I metabolization. We aimed to summarize and investigate the current evidence regarding the frequency of CYP2D6, CYP2C9, CYP2C...
Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients [0.03%]
Darolutamide在小鼠体内的药代动力学性质：对非对映异构体、关键活性代谢物和互变异构现象的评估及其对癌症患者的用药影响
Neeraj K Saini,Bhavesh B Gabani,Umesh Todmal et al.
Neeraj K Saini et al.
Background: Darolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. Hitherto, no stereoselective pharmacokinetic data have been published pertaining to darolutamide and i...
Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations [0.03%]
氨磺必利的口服吸收增强及其药动学和药效学评价
Prajapati Jagruti B,Sawant Krutika K,Bhramanand Dubey
Prajapati Jagruti B
Background: Many CNS drugs have low bioavailability due to their poor water solubility of extensive first-pass metabolism and hence have less effectiveness. ...
Carbon-carbon Bond Cleavage Catalyzed by Human Cytochrome P450 Enzymes: α-ketol as the Key Intermediate Metabolite in Sequential Metabolism of Olanexidine [0.03%]
人类细胞色素P450酶催化的碳-碳键断裂：α-酮基作为奥拉硝氯中间代谢物的关键中间体
Yiding Hu,Yi Xiao,Zhesui Rao et al.
Yiding Hu et al.
Background: Carbon-carbon bond cleavage of a saturated aliphatic moiety is rarely seen in xenobiotic metabolism. Olanexidine (Olanedine®), containing an n-octyl (C8) side chain, was mainly metabolized to various shortene...
Assessment of Inhibition of Bovine Hepatic Cytochrome P450 by 43 Commercial Bovine Medicines Using a Combination of In Vitro Assays and Pharmacokinetic Data from the Literature [0.03%]
基于体外实验和文献报道的药动学数据评估43种商业化牛用药对牛肝细胞色素P450抑制作用的研究
Steven X Hu,Chase A Mazur,Kenneth L Feenstra
Steven X Hu
Background: There has been a lack of information about the inhibition of bovine medicines on bovine hepatic CYP450 at their commercial doses and dosing routes. ...